February 13th, 2017 – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that Gregory OD Smith will join its Board of Directors. The appointment comes as the company prepares to build its facility in Janesville, Wisconsin, after receiving its construction permit from the U.S. Nuclear Regulatory Commission last year. The SHINE facility will produce molybdenum-99 (moly‑99) and other medical isotopes.
“Gregory’s 39 years of leadership experience in the nuclear industry and his track record of creating effective partnerships will add significant value to our company as we begin building our first isotope facility,” said Gregory Piefer, founder and CEO of SHINE. “We appreciate his willingness to serve as director and look forward to benefiting from his judgment and counsel.”
An industry veteran, Mr. Smith has served as the Chairman of Urenco UK and Urenco’s Chief Culture Officer. Prior to that, he served as Chairman of the Board and Chief Executive Officer for Louisiana Energy Services (LES), a uranium enrichment company wholly owned by Urenco. As CEO of LES, Mr. Smith oversaw the completion of construction and startup of the National Enrichment Facility in New Mexico. Mr. Smith joined LES in September of 2007 as Chief Operating Officer with overall responsibility for regulatory affairs, engineering, construction operations and expansion activities for the project.
Prior to joining LES, Mr. Smith worked for Ontario Power Generation (OPG). From 2002‑2006, Mr. Smith served as the Senior Vice President for the 4-unit Darlington Nuclear station. In December 2006, Mr. Smith was appointed to the position of Senior Vice President Nuclear Generation and Services responsible for the strategic direction, planning, and execution for the refurbishment of OPG’s Darlington nuclear station and the company’s new nuclear construction project. From 1992-2002, Mr. Smith worked at Energy Northwest where he held several positions, including Operations Division Manager, Plant General Manager, Vice President Nuclear Operations, and Vice President Generation.
Molybdenum-99 (moly-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including moly‑99.
About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In June of 2016, SHINE signed a moly-99 supply agreement with HTA Co., Ltd. (HTA), the largest Chinese producer and distributor of radiopharmaceuticals. Learn more at http://shinemed.com.